This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Most patients aren't experienced enough to be competent in handling a scary new diagnosis, but here's how self-reflection can make a difference during recovery.
In this episode, hosts are joined by Grazia Aleppo, MD, for a discussion on the use of inhaled insulin following the INHALE-3 trial and relevant updates in diabetes technology at ADA 2024.
Written by Willy Frick A man in his 50s was at home with his family when they heard a thud and rushed into the room to find him unconscious with agonal respirations. His daughter immediately started CPR and another family member called EMS. When EMS arrived the patient was in ventricular fibrillation. They shocked him twice before return of spontaneous circulation.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
(MedPage Today) -- ORLANDO -- An investigational triple-hormone receptor agonist improved metabolic profiles of people with obesity with or without type 2 diabetes, an exploratory biomarker analysis of a phase II trial found. After 36 weeks.
Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. Women experienced greater weight loss and the same symptom benefits compared with men.
(MedPage Today) -- ORLANDO -- For type 1 diabetes patients, switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) maintained glycemic control -- for those who used it as intended, the INHALE 3 trial showed.
(MedPage Today) -- ORLANDO -- For type 1 diabetes patients, switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) maintained glycemic control -- for those who used it as intended, the INHALE 3 trial showed.
In the special on-site ADA 2024 episode, hosts are joined by the ADA's Chief Scientific and Medical Officer Robert Gabbay, MD, PhD, to discuss the newly formed Obesity Association.
(MedPage Today) -- ORLANDO -- Putting type 2 diabetes patients on an automated insulin delivery (AID) pump improved glycemic control, the SECURE-T2D pivotal trial showed. Type 2 diabetes patients started on the Omnipod 5 System, currently approved.
MOMENTUM trial data shows pemvidutide reduced body weight by 15.6%, with 78.1% fat loss, highlighting the GLP-1/Glucagon receptor agonist's ability to achieve significant weight reduction and minimal muscle loss.
In a translational study involving animal models and human subjects, Lv et al. demonstrate that arachidonic acid (AA) exhibits cardioprotective effects in diabetic myocardial ischemia, suggesting a departure f.
First rib tumors are extremely rare. Its compression of neurovascularity can easily lead to severe complications such as thoracic outlet syndrome, so early surgical resection is crucial. However, there is no s.
Most metastatic lung tumors present as solid nodules on chest computed tomography (CT). In contrast, ground-glass opacity on chest computed tomography usually suggests low-grade malignant lesions such as adeno.
BackgroundIschemia with non-obstructive coronary arteries (INOCA) is a major clinical entity that involves potentially 20%–30% of patients with chest pain. INOCA is typically attributed either to coronary microvascular disease and/or vasospasm, but is likely distinct from classical coronary artery disease (CAD).ObjectivesTo gain insights into the etiology of INOCA and CAD, RNA sequencing of whole blood from patients undergoing both stress testing and elective invasive coronary angiography (ICA)
The prognostic value of cellular retinoic acid-binding protein 2 (CRABP2), in lung cancer patients remains to be uncertained. Therefore, our research attempted to assess the relationship between CRABP2 and sur.
Tricuspid regurgitation (TR) is a well-known complication after transvenous pacemaker implantation that is less well described for leadless pacemakers (LPs).1 Previous studies have reported discordant data regarding the incidence of significant TR with LP compared to transvenous systems.
To explore the independent predictors of pathological mediastinal lymph node (pN2) metastasis in clinical stage IA (cIA) pure-solid non-small cell lung cancer (NSCLC) patients, and to find an appropriate metho.
Early recurrence of atrial tachyarrhythmias (ERAT) within 3 months of thermal ablation for atrial fibrillation (AF) is common and often considered transient. Pulsed field ablation (PFA) is a nonthermal energy source in which ERAT is not well described.
Eosinophilic meningitis (EM) presents a diagnostic challenge due to its varied etiologies, encompassing both infectious and non-infectious causes. Typically, cerebrospinal fluid (CSF) devoid of eosinophils serves as the norm, with their presence indicating a potential underlying condition such as parasitic infections or other systemic disorders.
Diabetic peripheral neuropathy (DPN) is the most prevalent complication of diabetes, and has been demonstrated to be independently associated with cardiovascular events and mortality. This aim of this study wa.
Direct oral anticoagulants (DOACs) reduce stroke risk in patients with device-detected atrial fibrillation (DD-AFib) but increase major bleeding risk. The time to benefit (TTB) and time to harm (TTH) are not well quantified.
Direct oral anticoagulants (DOACs) are the preferred anticoagulant strategy for stroke prevention in patients with atrial fibrillation. Concomitantly, non-dihydropyridine (non-DHP) calcium channel blockers (CCBs) and beta-blockers are commonly utilized for rate control in this cohort. Existing research has shown a potential increase in bleeding risk associated with administering non-DHP CCBs with anticoagulants; however, these findings remain tentative, attributed to variations in study design,
Catheter ablation has become the most effective rhythm control strategy in treating atrial fibrillation (AF), preventing AF recurrence and delaying its progression to persistent AF better than antiarrhythmic drugs. Furthermore, among patients with heart failure, both reduced and preserved ejection fraction, catheter ablation reduces heart failure hospitalizations and mortality.
Publication date: Available online 23 June 2024 Source: The American Journal of Cardiology Author(s): Ebenezer Oni, Ellen Boakye, Gregg S. Pressman, Zeina Dardari, Kunal Jha, Moyses Szklo, Matthew Budoff, Khurram Nasir, Timothy M. Hughes, Michael J.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content